Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression
Open Access
- 8 October 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 17 (02), 331-336
- https://doi.org/10.1017/s1461145713001119
Abstract
Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between indiKeywords
This publication has 23 references indexed in Scilit:
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled TrialAmerican Journal of Psychiatry, 2013
- Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant DepressionBiological Psychiatry, 2010
- Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to anN-Methyl-D-Aspartate AntagonistThe Journal of Clinical Psychiatry, 2009
- Brain macrostructural and microstructural abnormalities in cocaine dependenceDrug and Alcohol Dependence, 2007
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major DepressionArchives of General Psychiatry, 2006
- Neurotrophins as synaptic modulatorsNature Reviews Neuroscience, 2001
- Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNFMolecular Brain Research, 1996
- Midazolam: The First Water‐soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and AnesthesiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1985
- COMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERSBritish Journal of Anaesthesia, 1985
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979